Update from BioCryst Pharmaceuticals regarding antiviral peramivir

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the Office of the Secretary, Department of Health & Human Services (HHS) has issued "HHS Secretary's Declaration for the Use of the Public Readiness and Emergency Preparedness Act for the Influenza Antiviral Peramivir." Notice of this Declaration was posted today in the Federal Register and can be found on the Web at:

http://www.thefederalregister.com/d.p/2009-10-02-E9-23761

This Declaration represents a required step before an Emergency Use Authorization (EUA) may be issued. Further information regarding the EUA process may be found in a policy review available from the U.S. Centers for Disease Control (CDC) and can be found on the Web at:

http://www.cdc.gov/eid/content/13/7/1046.htm

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Healthy lifestyle choices can offset genetic risk for brain diseases